What this is
- How it works
- How it works isn't classified yet
- Tested for
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor and 1 more
- Main trialPhase 1
- “The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.”In the company’s words, NCT07165132 on ClinicalTrials.gov
Other drugs for GEP-NET
- CAM2029Camurus AB · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- 177Lu-edotreotide PRRTITM Solucin GmbH · Phase 3
- VMT-α-NETPerspective Therapeutics · Phase 1/2
- CVM-1118TaiRx, Inc. · Phase 2
- Lu-DOTA-TATENovartis Pharmaceuticals · Phase 2
Coming up1
- Feb 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Feb 2027 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026